Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
Abstract
3064 Background: ICIs are associated with irAEs. We describe the incidence of irAEs in patients with solid tumors receiving ICIs and its correlation with efficacy. Methods: We retrospectively analyzed all patients with solid tumors receiving ICIs in our center. IrAEs were graded according CTCAE v4.0. Kaplan Meier and log-rank tests were used to evaluate progression-free (PFS) and overall survivals (OS). Analyses were performed using SPSS v24 package. Results: From March 2014 to January 2018, 178 patients received ICIs. Median age was 64.1 [33-88] years, 72% were male. Most frequent tumors were lung (63.5%), bladder (14.6%) and melanoma (11.8%). 96% presented advanced disease. Most common used ICIs were nivolumab (38.2%), pembrolizumab (28.7%) and atezolizumab (17.4%). ICIs were used as monotherapy (74.7%) or in combination with ICI (3.4%), chemotherapy (17.4%) or targeted therapies (4.5%). Median duration of immunotherapy was 6.9 [0.7-46.3] months. 95 (53.4%) patients developed 158 irAEs with a median number per patient of 1.2 [0-4]. Most frequent irAE was rash (24.7%) followed by diarrhea (17.7%), hypothyroidism (9.5%), arthritis (6.9%), hyperthyroidism (3.8%), pneumonitis (3.2%) and mucositis (3.2%). Median time to the onset irAEs was 53.2 [11-490] days. 12 (6.7%) patients presented grade (G) 3-4 irAEs: 5 G-3 diarrhea, 2 G-3-4 liver dysfunction, 1 G-3 pneumonitis, 1 G-3 hypopituitarism, 1 G-3 mucositis, 1 G-3 arthritis and 1 G-3 nephritis. There were 2 (1.1%) treatment-related deaths due to pneumonitis. 21.3% patients required steroids for irAEs management. 8.4% patients discontinued treatment due to irAEs. 73.9% irAEs had improved at the time of analysis. OS was superior in patients with advanced disease experiencing irAEs: 37.3 [95%CI, 19.2-51.4] vs 7.8 [95%CI, 4.9-10.8] months (p < 0.0001). Similarly, PFS was longer: 7.9 [95%CI, 4.4-11.4] vs 2.6 [95%CI, 2.0-3.2] months (p < 0.0001). Conclusions: There was a significant correlation between presence of irAEs and outcomes in patients with advanced solid tumors treated with ICIs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Across disease sites, patients who experience IRAEs while on therapy with anti-PD-1 and anti-PD-L1 antibodies have been documented to experience improved outcomes as measured by overall response rate, progression-free survival and overall survival.
“Across disease sites, patients who experience IRAEs while on therapy with anti-PD-1 and anti-PD-L1 antibodies have been documented to experience improved outcomes as measured by overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) [13–20].”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [13]
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 301 · see citing works
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0618 · Cited by 207 · see citing works
Thomas, M. F., Slowikowski, K., Manakongtreecheep, K., Sen, P., Samanta, N., Tantivit, J., Nasrallah, M., Zubiri, L., Smith, N. P., Tirard, A. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02895-x · Cited by 86 · see citing works
“The rigorous study of organ-specific IRAEs is essential for decoupling ICI efficacy and toxicity, given their intrinsic correlation 59 .”
Cortellini, A., Verna, L., Porzio, G., Bozzetti, F., Palumbo, P., Masciocchi, C., Cannita, K., Parisi, A., Brocco, D., Tinari, N., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12965 · Cited by 66 · see citing works
Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study
Koks, M., Ocak, G., Suelmann, B. B. M., Hulsbergen-Veelken, C. A. R., Haitjema, S., Vianen, M. E., Verhaar, M. C., Kaasjager, K. A. H., & Khairoun, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252978 · Cited by 49 · see citing works
“This hypothesis is suggested by recent studies showing improved progression-free and overall survival in ICPi users who develop irAE [35,36].”
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 49 · see citing works
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 48 · see citing works
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41 · see citing works
Wu, C., Yang, C., Peng, M., Huang, P., Chang, C., Yeh, K., Chen, C., Wang, C., Hsu, C., Chen, I., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07508-7 · Cited by 42 · see citing works
George, S., Bell, E. J., Zheng, Y., Kim, R., White, J. C., Devgan, G., Smith, J., Lal, L. S., Engel-Nitz, N. M., & Liu, F. X. (2021) · The Oncologist · doi:10.1002/onco.13812 · Cited by 40 · see citing works
Chieng, J. H. L., Htet, Z. W., Zhao, J. J., Tai, E. S., Tay, S. H., Huang, Y., Wong, A. S. C., & Yang, S. P. (2022) · Cancers · doi:10.3390/cancers14112687 · Cited by 40 · see citing works
Shi, Y., Fang, J., Zhou, C., Liu, A., Wang, Y., Meng, Q., Ding, C., Ai, B., Gu, Y., Yao, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14274 · Cited by 37 · see citing works
Peravali, M., Gomes-Lima, C. J., Tefera, E. A., Baker, M., Sherchan, M., Farid, S., Burman, K. D., Constantinescu, F., & Veytsman, I. G. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i2.103 · Cited by 31 · see citing works
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications
Güven, D. C., Aktaş, B. Y., Şimşek, C., & Aksoy, S. (2020) · Future Oncology · doi:10.2217/fon-2019-0783 · Cited by 25 · see citing works
Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24 · see citing works
Zhou, Y. L., Chen, H., Tang, L. M., Feng, Y., Tao, Y., Huang, L., Lou, N., & Shi, Y. (2023) · Immunotherapy · doi:10.2217/imt-2022-0028 · Cited by 17 · see citing works
Hino, C., Nishino, K., Pham, B., Jeon, W. J., Nguyen, M., & Cao, H. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993622 · Cited by 14 · see citing works
Lui, D. T. W., Lee, C., Tang, V., Fong, C. H. Y., Lee, A. C. H., Chiu, J. W. Y., Leung, R. C. Y., Kwok, G. W., Li, B. C. W., Cheung, T. T., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.017 · Cited by 14 · see citing works
Cordes, L. M., Davarpanah, N. N., Reoma, L. B., Gasmi, B., Quezado, M., Khan, O. I., Nath, A., & Apolo, A. B. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2534 · Cited by 13 · see citing works
Ma, V. T., Su, C., Hu, M. M., Taylor, J. M. G., Daignault-Newton, S., Kellezi, O., Dahl, M., Shah, M. A., Erickson, S., Lora, J., et al. (2021) · Urologic oncology · doi:10.1016/j.urolonc.2021.01.006 · Cited by 12 · see citing works
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 9 · see citing works
Guardamagna, M., Berciano-Guerrero, M., Lavado-Valenzuela, R., Auclin, É., Onieva-Zafra, J.-L., Plaza-Andrades, I., Oliver, J., Garrido-Aranda, A., Pérez-Ruiz, E., Álvarez, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11054-2 · Cited by 8 · see citing works
“The available evidence focuses on TRAE as a result of ICI, which may not be applicable to iBRAF/MEK given their distinct mechanisms of action 31 .”
Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
Dawidowska, A., Jagodzińska-Mucha, P., Koseła-Paterczyk, H., Jaczewska, S., Sobczuk, P., Chełstowska, M., Kowalska, M. M., Badziak-Sterczewska, H., Poleszczuk, J., Rutkowski, P. L., et al. (2022) · Cancers · doi:10.3390/cancers14051248 · Cited by 9 · see citing works
“Recent data have shown that the irAEs may correlate with the response to ICIs, but the evidence is still conflicting in melanoma patients [16,17].”
BackgroundAbdihamid, O., Athman, A., & Rugambwa, T. K. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1314 · Cited by 9 · see citing works
“(Continued) Vitale et al [82] mRCC 167 Nivolumab OS (20.1 months; HR: 0.38; 95% CI: 0.23–0.63) PFS (7.86 months; HR: 0.44; 95% CI: 0.29–0.66) ORR (27.3% versus 13.7%; OR: 2.36; 95% CI: 1.03–5.44) DCR (68.8% versus 48%; OR: 2.4; 95% CI: 1.23–4.67) Verzoni et al [83] RCC 389 Nivolumab OS (HR: 0.57; 95% CI: 0.35–0.93; p…”
BackgroundInfluentialFreitas, J. D. A. S., Bendicho, M. T., & Júnior, A. D. F. S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231171881 · Cited by 5 · see citing works
Barnet, M. B., Jackson, K., Masle‐Farquhar, E., Russell, A., Burnett, D. L., Chye, A., Jara, C., Faulks, M. L., Mawson, A., Peters, T. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314258122 · Cited by 6 · see citing works
Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series
Pergolini, D., Botticelli, A., Fascetti, R., et al. (2022) · Applied Sciences · doi:10.3390/app122412994 · Cited by 4 · see citing works
Vlachou, E., Johnson, B. A., McConkey, D. J., Hahn, N. M., Jing, Y., Russell, S., Stairiker, D., Rosen, A., Casciola-Rosen, L. A., & Hoffman-Censits, J. H. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0039 · Cited by 5 · see citing works
“In many cancers, ICI-related immune toxicity correlates with better treat-ment response (15–17).”
Ye, Z., Zheng, S., Chen, J., Zhang, Y., Yang, S., Hong, Y., Yang, H., Xuan, Z., & Zhao, Q. D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108738 · Cited by 2 · see citing works
Clonal redemption of B cells in cancer
McCaw, T. R., Lofftus, S. Y., & Crompton, J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277597 · Cited by 2 · see citing works
How to manage side effects of immunotherapy
Kopecký, J., & Kubeček, O. (2020) · Onkologie · doi:10.36290/xon.2020.049 · Cited by 2 · see citing works
- Authors
- Riudavets, M., Barba, A., Maroto, P., SULLIVAN, I. G., Anguera, G., Páez, D., del Carpio, L., Callejo, A., Gonzalez Blanco, C., Garcia Planellas, E., Castillo, D., Facundo, C., Genua, I., Martin Lorente, C., Virgili, A., Sebio, A., Gallego, O., Lopez-Pousa, A., Barnadas, A., & Majem, M.
- Affiliations
- Hospital de Sant Pau (ES)
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;
- Puigvert Foundation (ES)
- Hospital de la Santa Creu i Sant Pai, Barcelona, Spain;
- Hospital Sant Pau, Barcelona, Spain;
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-20
- Volume
- 36
- Issue
- 15_suppl
- Pages
- 3064-3064
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2891948100
- Cited by
- 32
- References
- 0
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 5 · 2019: 5
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, solid tumors, immune-related pneumonitis, non-relapse mortality, progression-free survival, overall survival, nivolumab, pembrolizumab, atezolizumab, corticosteroid therapy, rash, diarrhea, hypothyroidism, liver dysfunction, pneumonitis, immunotherapy efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
